中国继续医学教育
中國繼續醫學教育
중국계속의학교육
China Continuing Medical Education
2015年
24期
56-57
,共2页
早期乳腺癌%Ki67表达水平%预后%分子分型
早期乳腺癌%Ki67錶達水平%預後%分子分型
조기유선암%Ki67표체수평%예후%분자분형
Early stage breast cancer%Ki67 expression level%Prognosis%Molecular subtypes
目的：探讨Ki67在早期乳腺癌患者中的表达情况，并分析其与临床病理指标的相关性。方法收集并回顾性分析福建医科大学附属漳州市医院2010年1月～2014年12月收治的236例女性早期乳腺癌患者的临床病理资料，分析Ki67的表达水平与早期乳腺癌其它临床病理指标的相关性。结果根据Ki67表达水平分为高表达（Ki67表达水平≥14%）和低表达（Ki67表达水平＜14%）。236例早期乳腺癌患者的Ki67的表达情况如下：Ki67高表达者有188例，高表达率达79.7%， Ki67低表达者有48例，低表达率达20.3%。进一步分析显示，Ki67的表达水平与早期乳腺癌患者年龄、肿瘤T分期、腋窝淋巴结转移、病理分级、雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER-2）状态均有关（P＜0.05）。按分子分型划分，早期乳腺癌的Luminal B型、HER-2过表达型和三阴性乳腺癌型的Ki67水平分别为34.3%、33.3%和55.6%，均高于Luminal A型（12.2%，P＜0.001）。早期乳腺癌的三阴性乳腺癌Ki67水平高于非三阴性乳腺癌（26.6%，P＜0.001）。结论早期乳腺癌患者Ki67水平与患者年龄、肿瘤T分期、腋窝淋巴结转移、病理分级以及ER、PR和HER-2状态有关，有望成为判断早期乳腺癌不同分子分型预后的重要辅助指标。
目的：探討Ki67在早期乳腺癌患者中的錶達情況，併分析其與臨床病理指標的相關性。方法收集併迴顧性分析福建醫科大學附屬漳州市醫院2010年1月～2014年12月收治的236例女性早期乳腺癌患者的臨床病理資料，分析Ki67的錶達水平與早期乳腺癌其它臨床病理指標的相關性。結果根據Ki67錶達水平分為高錶達（Ki67錶達水平≥14%）和低錶達（Ki67錶達水平＜14%）。236例早期乳腺癌患者的Ki67的錶達情況如下：Ki67高錶達者有188例，高錶達率達79.7%， Ki67低錶達者有48例，低錶達率達20.3%。進一步分析顯示，Ki67的錶達水平與早期乳腺癌患者年齡、腫瘤T分期、腋窩淋巴結轉移、病理分級、雌激素受體（ER）、孕激素受體（PR）和人錶皮生長因子受體2（HER-2）狀態均有關（P＜0.05）。按分子分型劃分，早期乳腺癌的Luminal B型、HER-2過錶達型和三陰性乳腺癌型的Ki67水平分彆為34.3%、33.3%和55.6%，均高于Luminal A型（12.2%，P＜0.001）。早期乳腺癌的三陰性乳腺癌Ki67水平高于非三陰性乳腺癌（26.6%，P＜0.001）。結論早期乳腺癌患者Ki67水平與患者年齡、腫瘤T分期、腋窩淋巴結轉移、病理分級以及ER、PR和HER-2狀態有關，有望成為判斷早期乳腺癌不同分子分型預後的重要輔助指標。
목적：탐토Ki67재조기유선암환자중적표체정황，병분석기여림상병리지표적상관성。방법수집병회고성분석복건의과대학부속장주시의원2010년1월～2014년12월수치적236례녀성조기유선암환자적림상병리자료，분석Ki67적표체수평여조기유선암기타림상병리지표적상관성。결과근거Ki67표체수평분위고표체（Ki67표체수평≥14%）화저표체（Ki67표체수평＜14%）。236례조기유선암환자적Ki67적표체정황여하：Ki67고표체자유188례，고표체솔체79.7%， Ki67저표체자유48례，저표체솔체20.3%。진일보분석현시，Ki67적표체수평여조기유선암환자년령、종류T분기、액와림파결전이、병리분급、자격소수체（ER）、잉격소수체（PR）화인표피생장인자수체2（HER-2）상태균유관（P＜0.05）。안분자분형화분，조기유선암적Luminal B형、HER-2과표체형화삼음성유선암형적Ki67수평분별위34.3%、33.3%화55.6%，균고우Luminal A형（12.2%，P＜0.001）。조기유선암적삼음성유선암Ki67수평고우비삼음성유선암（26.6%，P＜0.001）。결론조기유선암환자Ki67수평여환자년령、종류T분기、액와림파결전이、병리분급이급ER、PR화HER-2상태유관，유망성위판단조기유선암불동분자분형예후적중요보조지표。
Objective This study aims to analyze the correlationship between Ki67 expression level and other clinical features in patients with early stage breast cancer. Methods We analyzed data of 236 female patients with early stage breast cancer treated in Zhangzhou Hospital of Fujian Medical University from January 2010 to December 2014 and focused on the relationship between Ki67 expression level and other clinical features. Results According to the expression level of Ki67 is high expression (Ki67 ≥ 14%) and low expression (Ki67<14%). The expression of Ki67 in 236 cases of early breast cancer was as follows, Ki67 high expression of 188 cases, high expression rate of 79.7%, Ki67 low expression of 48 cases, low expression rate of 20.3%. Significant difference was found between the Ki67 expression level and other clinical features, such as age, tumor size, axillary lymph node status, histological grade and the expression level of estrogen receptor (ER), progesterone receptor (PR) and human epidermalgrowth factor receptor-2 (HER-2) ( P<0.05). The Ki67 expression levels in Luminal B (34.3%), HER-2 (33.3%), and triple-negative (55.6%) subtypes of early stage breast cancer were significantly higher than that in the luminal A subtype (12.2%, P<0.001). The Ki67 expression level in triple-negative subtype was significantly higher than that in the non-triple-negative subtype (26.6%, P<0.001) for the early stage breast cancer. Conclusion For early stage breast cancers, Ki67 expression level is signiifcantly correlated with other clinical features, such as age, tumor size, axillary lymph node status, histological grade and the expression level of ER, PR and HER-2, which may serve as a useful prognostic marker in the treatment of early stage breast cancer.
